knowledge -WSS

knowledge

author：comprehensive 2025-09-30 17:03:55 - browse：871

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： US soldier in North Korean custody after crossing DMZ line

knowledge

focus

WSS

Twill hunts for pharma partner to market its depression app

Twill hunts for pharma partner to market its depression app

Lack of darker skin in textbooks, journals harms patients of color

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Texas Department of Public Safety speaks out on migrant abuse allegations

focus

knowledge

entertainment

Heart attack and stroke risk calculators need revising

DeSantis talks Trump, trans issues and 'what wokeness is'

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

House passes resolution saying Israel isn't a 'racist or apartheid state'

Sports medicine is finally prioritizing gender equality

Ending racial health disparities hinges on penalties, political will

Moonlake's readout produced a cash windfall. Risks remain

FDA seeking to stop procedures at two unregulated stem cell clinics

In Memoriam: Notable people who died in 2023

Biden administration sends mixed signals on US soldier who crossed into North Korea

focus

Mass General totes up its waste in a move to tackle climate change

Driven by the pandemic, applicants flood public health schools

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Why Congress must ban federal programs from using QALYs

Robert Kennedy Jr.'s presidential campaign attracts GOP

EF3 tornado rips through North Carolina amid extreme weather nationwide

knowledge

knowledge

focus

focus